Business
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025Cash, cash equivalents, and investments of $152.4 million as of March 31, 2025; expected to be sufficient to fund operations into Q4 of 2027 CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical
About this update from Black Diamond Therapeutics, Inc.
[{"type":"image","alt":"Black Diamond Therapeutics, Inc","displaySize":"","headline":null,"caption":"Black Diamond Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/497f244e89de775874fac406d50e11cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vwkphi42thFYY0QCBIsk8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/497f244e89de775874fac406d50e11cb","width":300,"height":89}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Expansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents, and investments of $152.4 million as of March 31, 2025; expected to be sufficient to fund operations into Q4 of 2027","length":145,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":394,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":348,"tagName":"p"},{"type":"text","content":"“We continue to execute on enrollment in our BDTX-1535 Phase 2 trial for the treatment of newly diagnosed patients with EGFRm NSCLC and look forward to providing a clinical update in the fourth quarter of 2025,” said Mark Velleca, M.D., Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics. “Our recently announced global licensing agreement with Servier for BDTX-4933 provides us with a strong cash position and runway into the fourth quarter of 2027. Pending FDA feedback in the fourth quarter of 2025, we believe we are well-positioned to begin pivotal development of BDTX-1535 in the first half of 2026.”","length":630,"tagName":"p"},{"type":"text","content":"Recent Developments & Upcoming Milestones:"...